SCHEMBL1229631

SCHEMBL1229631

OCc1ccc(F)c2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.44
LMNA P02545 3/20 0.41
HTT P42858 2/20 0.41
MAPT P10636 2/20 0.41
HPGD P15428 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
CYP2A6 P11509 1/20 0.39
KDM4E B2RXH2 3/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
NPC1 O15118 1/20 0.38
GAA P10253 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
APOBEC3G Q9HC16 1/20 0.38
SLC6A4 P31645 3/20 0.38
SLC6A3 Q01959 3/20 0.38
GCGR P47871 1/20 0.38
FFAR1 O14842 1/20 0.38
SIGMAR1 Q99720 1/20 0.36
NPBWR1 P48145 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30975082 1.00 DAO (0.44) DAOLMNAHTTMAPTHPGD
SCHEMBL15353259 0.86 DAO (0.44) DAOLMNAMAPTHPGDCYP2A6
SCHEMBL29602459 0.84 CYP2A6 (0.48) LMNAHTTMAPTCYP2A6KDM4E
SCHEMBL431656 0.84 CYP2A6 (0.48) LMNAHTTMAPTCYP2A6KDM4E
SCHEMBL15352024 0.79 DAO (0.46) DAOLMNAHTTMAPTHPGD
SCHEMBL8852085 0.79 DAO (0.42) DAOLMNAHTTMAPTHPGD
SCHEMBL5236603 0.79 DAO (0.42) DAOLMNAHTTMAPTHPGD
SCHEMBL8429673 0.79 DAO (0.46) DAOLMNAHTTMAPTHPGD
SCHEMBL3594153 0.79 DAO (0.42) DAOLMNAHTTMAPTHPGD
SCHEMBL30306116 0.79 DAO (0.42) DAOLMNAHTTMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250268844-A1 ANTICANCER AGENTS BASED ON CYCLOPENTENONES UNIV OF CRETE (GR) 2025-08-28 US disclosed
EP-4565220-A1 ANTICANCER AGENTS BASED ON CYCLOPENTENONES University of Crete (GR) 2025-06-11 EP disclosed
WO-2024027947-A1 ANTICANCER AGENTS BASED ON CYCLOPENTENONES UNIVERSITY OF CRETE (GR) 2024-02-08 WO disclosed
EP-4316476-A1 ANTICANCER AGENTS BASED ON CYCLOPENTENONES University of Crete (GR) 2024-02-07 EP disclosed
US-9505753-B2 Inhibitors of D-amino acid oxidase THE JOHNS HOPKINS UNIVERSITY (US) 2016-11-29 US disclosed
US-20150218156-A1 INHIBITORS OF D-AMINO ACID OXIDASE THE JOHNS HOPKINS UNIVERSITY (US) 2015-08-06 US disclosed
EP-2841429-A1 TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES Sumitomo Chemical Company Limited (JP) 2015-03-04 EP disclosed
EP-2841433-A1 TETRAZOLINONE COMPOUNDS AND ITS USE Sumitomo Chemical Company Limited (JP) 2015-03-04 EP disclosed
WO-2014025993-A1 INHIBITORS OF D-AMINO ACID OXIDASE THE JOHNS HOPKINS UNIVERSITY (US) 2014-02-13 WO disclosed
WO-2013162077-A1 TETRAZOLINONE COMPOUNDS AND ITS USE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-10-31 WO disclosed
WO-2013162072-A1 TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-10-31 WO disclosed
US-20120190701-A1 RENIN INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-07-26 US disclosed
EP-2467385-A1 RENIN INHIBITORS Merck Canada Inc. (CA) 2012-06-27 EP disclosed
WO-2011020193-A1 RENIN INHIBITORS MERCK FROSST CANADA LTD. (CA) 2011-02-24 WO disclosed
US-20050245572-A1 Naphthyl ether compounds and their use OLINK AB (SE) 2005-11-03 US disclosed
EP-1546101-A1 NAPHTHYL ETHER COMPOUNDS AND THEIR USE AstraZeneca AB (SE) 2005-06-29 EP disclosed
WO-2004022539-A1 NAPHTHYL ETHER COMPOUNDS AND THEIR USE ASTRAZENECA AB (SE) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150218156-A1 INHIBITORS OF D-AMINO ACID OXIDASE DDO, DAO, GRIN2A DAO 2/4885LMNA 4815/4885HTT 4620/4885
US-20250268844-A1 ANTICANCER AGENTS BASED ON CYCLOPENTENONES MCL1, CCNE1, CCNI DAO 4343/4885LMNA 403/4885HTT 3451/4885
US-20120190701-A1 RENIN INHIBITORS REN, ACE, AGTR1 DAO 1106/4885LMNA 422/4885HTT 2874/4885
US-20050245572-A1 Naphthyl ether compounds and their use NR4A1, NPM1, H1-4 DAO 4529/4885LMNA 45/4885HTT 1609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.